nach oben

Erschienen in:

01.02.2011 | Review

Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications

verfasst von: Armen Yuri Gasparyan, Antonios Stavropoulos-Kalinoglou, Dimitri P. Mikhailidis, Karen M. J. Douglas, George D. Kitas

Erschienen in: Rheumatology International | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Patients with rheumatoid arthritis (RA) are at high risk of cardiovascular events. Platelet biomarkers are involved in inflammation, atherosclerosis and thrombosis. Cardiovascular and RA-associated factors can alter the structure and function of platelets, starting from megakaryocytopoiesis. Reactive megakaryocytopoiesis increases circulating platelets count and triggers hyperactivity. Hyperactive platelets target synovial membranes with subsequent local rheumatoid inflammation. Hyperactive platelets interact with other cells, and target the vascular wall. Accumulating evidence suggests that disease modifying anti-rheumatic drugs (DMARD) decrease platelet activity.

Alamanos Y, Voulgari PV, Drosos AA (2006) Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 36:182–188PubMedCrossRef

Gabriel SE (2008) Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 121(10 Suppl 1):S9–S14PubMedCrossRef

Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 46:862–873PubMedCrossRef

DeMaria AN (2002) Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 89(6A):33D–38DPubMedCrossRef

Kitas GD, Erb N (2003) Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42:607–613CrossRef

Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD (2010) The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol (In press)

Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36–40PubMed

Nicola PJ, Crowson CS, Maradit-Kremers H, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE (2006) Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 54:60–67PubMedCrossRef

Lip GY, Gibbs CR (1999) Does heart failure confer a hypercoagulable state? Virchow’s triad revisited. J Am Coll Cardiol 33:1424–1426PubMedCrossRef

10.

Ahnert AM, Freudenberger RS (2008) What do we know about anticoagulation in patients with heart failure? Curr Opin Cardiol 23:228–232PubMedCrossRef

11.

del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745PubMedCrossRef

12.

Szekanecz Z, Koch AE (2008) Vascular involvement in rheumatic diseases: ‘vascular rheumatology’. Arthritis Res Ther 10:224PubMedCrossRef

13.

Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963PubMedCrossRef

14.

Stevens RJ, Douglas KM, Saratzis AN, Kitas GD (2005) Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 7:1–24PubMedCrossRef

15.

Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD (2002) Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1:338–347PubMedCrossRef

16.

Montecucco F, Mach F (2009) Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 48:11–22CrossRef

17.

Palmer DG, Hogg N, Revell PA (1986) Lymphocytes, polymorphonuclear leukocytes, macrophages and platelets in synovium involved by rheumatoid arthritis. A study with monoclonal antibodies. Pathology 18:431–437PubMedCrossRef

18.

Farr M, Wainwright A, Salmon M, Hollywell CA, Bacon PA (1984) Platelets in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 4:13–17PubMedCrossRef

19.

Endresen GK (1989) Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 9:19–24PubMedCrossRef

20.

Endresen GK, Førre O (1992) Human platelets in synovial fluid. A focus on the effects of growth factors on the inflammatory responses in rheumatoid arthritis. Clin Exp Rheumatol 10:181–187PubMed

21.

Endresen GK (1981) Investigation of blood platelets in synovial fluid from patients with rheumatoid arthritis. Scand J Rheumatol 10:204–208PubMedCrossRef

22.

Schmitt-Sody M, Klose A, Gottschalk O, Metz P, Gebhard H, Zysk S, Eichhorn ME, Hernandez-Richter TM, Jansson V, Veihelmann A (2005) Platelet–endothelial cell interactions in murine antigen-induced arthritis. Rheumatology (Oxford) 44:885–889CrossRef

23.

Schmitt-Sody M, Metz P, Gottschalk O, Birkenmaier C, Zysk S, Veihelmann A, Jansson V (2007) Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets 18:365–372PubMedCrossRef

24.

Schmitt-Sody M, Metz P, Klose A, Gottschalk O, Zysk S, Hausdorf J, Veihelmann A, Jansson V (2007) In vivo interactions of platelets and leucocytes with the endothelium in murine antigen-induced arthritis: the role of P-selectin. Scand J Rheumatol 36:311–319PubMedCrossRef

25.

Waguri-Nagaya Y, Otsuka T, Sugimura I, Matsui N, Asai K, Nakajima K, Tada T, Akiyama S, Kato T (2000) Synovial inflammation and hyperplasia induced by gliostatin/platelet-derived endothelial cell growth factor in rabbit knees. Rheumatol Int 20:13–19PubMedCrossRef

26.

Shapleigh C, Valone FH, Schur PH, Goetzl EJ, Austen KF (1980) Platelet-activating activity in synovial fluids of patients with rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and noninflammatory arthropathies. Arthritis Rheum 23:800–807PubMedCrossRef

27.

Weissbarth E, Baruth B, Mielke H, Liman W, Deicher H (1982) Platelets as target cells in rheumatoid arthritis and systemic lupus erythematosus: a platelet specific immunoglobulin inducing the release reaction. Rheumatol Int 2:67–73PubMedCrossRef

28.

Jagroop IA, Kakafika AI, Mikhailidis DP (2007) Platelets and vascular risk: an option for treatment. Curr Pharm Des 13:1669–1683PubMedCrossRef

29.

Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. J Clin Invest 115:3339–3347PubMedCrossRef

30.

Harrison P, Goodall AH (2008) “Message in the platelet”—more than just vestigial mRNA! Platelets 19:395–404PubMedCrossRef

31.

Lerkevang Grove E, Hvas AM, Dalby Kristensen S (2009) Immature platelets in patients with acute coronary syndromes. Thromb Haemost 101:151–156

32.

Davì G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482–2494PubMedCrossRef

33.

Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N (2008) Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets 19:146–154PubMedCrossRef

34.

Yetkin E (2008) Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. Thromb Haemost 100:3–4PubMed

35.

Bath PM, Butterworth RJ (1996) Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 7:157–161PubMedCrossRef

36.

Boos CJ, Lip GY (2007) Assessment of mean platelet volume in coronary artery disease—what does it mean? Thromb Res 120:11–13PubMedCrossRef

37.

Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP (2000) Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets 11:28–32PubMedCrossRef

38.

Javela K, Kekomäki R (2007) Mean platelet size related to glycoprotein-specific autoantibodies and platelet-associated IgG. Int J Lab Hematol 29:433–441PubMedCrossRef

39.

Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP (2003) Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost 9:177–190PubMedCrossRef

40.

Avramakis G, Papadimitraki E, Papakonstandinou D, Liakou K, Zidianakis M, Dermitzakis A, Mikhailidis DP, Ganotakis ES (2007) Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. Platelets 18:16–23PubMedCrossRef

41.

Muscari A, De Pascalis S, Cenni A, Ludovico C, Castaldini N, Antonelli S, Bianchi G, Magalotti D, Zoli M (2008) Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost 99:1079–1084PubMed

42.

Colkesen Y, Acil T, Abayli B, Yigit F, Katircibasi T, Kocum T, Demircan S, Sezgin A, Ozin B, Muderrisoglu H (2008) Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation? Blood Coagul Fibrinolysis 19:411–414PubMedCrossRef

43.

Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R (2002) Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 117:399–404PubMedCrossRef

44.

Martin JF, Bath PM, Burr ML (1991) Influence of platelet size on outcome after myocardial infarction. Lancet 338:1409–1411PubMedCrossRef

45.

Bath P, Algert C, Chapman N, Neal B (2004) PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 35:622–626PubMedCrossRef

46.

Coban E, Adanir H (2008) Platelet activation in patients with familial Mediterranean fever. Platelets 19:405–408PubMedCrossRef

47.

Milovanovic M, Nilsson E, Järemo P (2004) Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta 343:237–240PubMedCrossRef

48.

Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, Kiraz S, Ertenli I, Calguneri M (2008) Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 75:291–294PubMedCrossRef

49.

Ertenli I, Kiraz S, Oztürk MA, Haznedaroğlu I, Celik I, Calgüneri M (2003) Pathologic thrombopoiesis of rheumatoid arthritis. Rheumatol Int 23:49–60PubMed

50.

Farr M, Scott DL, Constable TJ, Hawker RJ, Hawkins CF, Stuart J (1983) Thrombocytosis of active rheumatoid disease. Ann Rheum Dis 42:545–549PubMedCrossRef

51.

Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA (2001) Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 96:776–781PubMedCrossRef

52.

Barradas MA, Stansby G, Hamilton G, Mikhailidis DP (1994) Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. Int Angiol 13:202–207PubMed

53.

Fink PC, Piening U, Fricke PM, Deicher H (1979) Platelet aggregation and aggregation inhibition by different antiglobulins and antiglobulin complexes from sera of patients with rheumatoid arthritis. Arthritis Rheum 22:896–903PubMedCrossRef

54.

Saeed SA, Gilani AH, Rasheed H, Bhatti FN, Atiq M, Qureshi A, Jafary R, Connor JD (2002) Plasma from rheumatoid patients taking low dose methotrexate enhances platelet aggregation. Res Commun Mol Pathol Pharmacol 111:69–76PubMed

55.

Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA (2002) Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 41:458–461CrossRef

56.

Alcalay M, Bontoux D, Peltier A, Vial MC, Vilde JM, Wautier JL (1981) C7 deficiency, abnormal platelet aggregation, and rheumatoid arthritis. Arthritis Rheum 24:102–103PubMedCrossRef

57.

Falus A, Merétey K, Bagdy D, Diószegi M, Böhm U, Csák E, Bozsóky S (1982) Beta-2-microglobulin-specific autoantibodies cause platelet aggregation and interfere with ADP-induced aggregation. Clin Exp Immunol 47:103–109PubMed

58.

Riddle JM, Bluhm GB, Pitchford WC, McElroy H, Jimenea C, Leisen J, Venkatasubramanian K (1981) A comparative study of platelet reactivity in arthritis. Ann N Y Acad Sci 370:22–29PubMedCrossRef

59.

Colli S, Maderna P, Tremoli E, Colombo F, Canesi B (1982) Platelet function in rheumatoid arthritis. Scand J Rheumatol 11:139–143PubMedCrossRef

60.

Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL (1997) A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 36:164–169PubMedCrossRef

61.

Sfikakis PP, Charalambopoulos D, Vaiopoulos G, Mavrikakis M (1999) Circulating P- and L-selectin and T-lymphocyte activation and patients with autoimmune rheumatic diseases. Clin Rheumatol 18:28–32PubMedCrossRef

62.

Meyer MF, Schmidt O, Hellmich B, Schatz H, Klein HH, Braun J (2007) Microvascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: relationship to soluble adhesion molecules and extraarticular manifestations. Rheumatol Int 28:145–152PubMedCrossRef

63.

Li G, Sanders JM, Phan ET, Ley K, Sarembock IJ (2005) Arterial macrophages and regenerating endothelial cells express P-selectin in atherosclerosis-prone apolipoprotein E-deficient mice. Am J Pathol 167:1511–1518PubMed

64.

Frenette PS, Wagner DD (1996) Adhesion molecules: part II. Blood vessels and blood cells. N Engl J Med 335:43–45PubMedCrossRef

65.

Chung I, Lip GY (2003) Virchow’s triad revisited: blood constituents. Pathophysiol Haemost Thromb 33:449–454PubMedCrossRef

66.

von Hundelshausen P, Weber C (2007) Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 100:27–40CrossRef

67.

McNicol A, Israels SJ (2008) Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc Hematol Disord Drug Targets 8:99–117PubMedCrossRef

68.

Sumariwalla PF, Malfait AM, Feldmann M (2004) P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor. Clin Exp Immunol 136:67–75PubMedCrossRef

69.

Ertenli I, Kiraz S, Arici M, Haznedaroglu IC, Calgüneri M, Celik I, Kirazli S (1998) P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis. J Rheumatol 25:1054–1058PubMed

70.

Bhatia GS, Sosin MD, Patel JV, Grindulis KA, Khattak FH, Davis RC, Lip GY (2009) Plasma indices of endothelial and platelet activation in rheumatoid disease: relationship to cardiovascular co-morbidity. Int J Cardiol 134:97–103PubMedCrossRef

71.

Ateş A, Kinikli G, Turgay M, Duman M (2004) Serum-soluble selectin levels in patients with rheumatoid arthritis and systemic sclerosis. Scand J Immunol 59:315–320PubMedCrossRef

72.

Bunescu A, Seideman P, Lenkei R, Levin K, Egberg N (2004) Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 31:2347–2355PubMed

73.

Hagberg IA, Lyberg T (2000) Blood platelet activation evaluated by flow cytometry: optimised methods for clinical studies. Platelets 11:137–150PubMedCrossRef

74.

Klinkhardt U, Harder S (2005) Flow cytometric measurement of platelet-leukocyte aggregates: a possible target to monitor platelet function? Semin Thromb Hemost 31:400–403PubMedCrossRef

75.

Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ (2001) Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 115:451–459PubMedCrossRef

76.

Matzdorff A (2005) Platelet function tests and flow cytometry to monitor antiplatelet therapy. Semin Thromb Hemost 31:393–399PubMedCrossRef

77.

Wang F, Wang NS, Yan CG, Li JH, Tang LQ (2007) The significance of platelet activation in rheumatoid arthritis. Clin Rheumatol 26:768–771PubMedCrossRef

78.

de Man FH, Nieuwland R, van der Laarse A, Romijn F, Smelt AH, Gevers Leuven JA, Sturk A (2000) Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy. Atherosclerosis 152:407–414PubMedCrossRef

79.

Preston RA, Coffey JO, Materson BJ, Ledford M, Alonso AB (2007) Elevated platelet P-selectin expression and platelet activation in high risk patients with uncontrolled severe hypertension. Atherosclerosis 192:148–154PubMedCrossRef

80.

Chung I, Choudhury A, Patel J, Lip GY (2009) Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 41:45–51PubMedCrossRef

81.

Koyama H, Maeno T, Fukumoto S, Shoji T, Yamane T, Yokoyama H, Emoto M, Shoji T, Tahara H, Inaba M, Hino M, Shioi A, Miki T, Nishizawa Y (2003) Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 108:524–529PubMedCrossRef

82.

Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA (2002) Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 46:1498–1503PubMedCrossRef

83.

Ardoin SP, Shanahan JC, Pisetsky DS (2007) The role of microparticles in inflammation and thrombosis. Scand J Immunol 66:159–165PubMedCrossRef

84.

Berckmans RJ, Nieuwland R, Tak PP, Böing AN, Romijn FP, Kraan MC, Breedveld FC, Hack CE, Sturk A (2002) Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 46:2857–2866PubMedCrossRef

85.

Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594PubMedCrossRef

86.

Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S, Lanzavecchia A (1998) Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 28:2760–2769PubMedCrossRef

87.

Sallusto F, Mackay CR (2004) Chemoattractants and their receptors in homeostasis and inflammation. Curr Opin Immunol 16:724–731PubMedCrossRef

88.

Kim KW, Cho ML, Kim HR, Ju JH, Park MK, Oh HJ, Kim JS, Park SH, Lee SH, Kim HY (2007) Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 56:1076–1086PubMedCrossRef

89.

Kyburz D, Corr M, Brinson DC, Von Damm A, Tighe H, Carson DA (1999) Human rheumatoid factor production is dependent on CD40 signaling and autoantigen. J Immunol 163:3116–3122PubMed

90.

Tamura N, Kobayashi S, Kato K, Bando H, Haruta K, Oyanagi M, Kuriyama M, Kipps TJ, Hashimoto H (2001) Soluble CD154 in rheumatoid arthritis: elevated plasma levels in cases with vasculitis. J Rheumatol 28:2583–2590PubMed

91.

McLaren M, Waring A, Galarraga B, Rudd A, Morley K, Belch JJ (2005) Investigation of platelet glycoprotein IIIa polymorphism using flow cytometry in patients with rheumatoid arthritis. Scand J Rheumatol 34:437–440PubMedCrossRef

92.

Jackson M, Ahmad Y, Bruce IN, Coupes B, Brenchley PE (2006) Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res Ther 8:R81PubMedCrossRef

93.

Weicht B, Maitz P, Kandler B, Fischer MB, Watzek G, Gruber R (2007) Activated platelets positively regulate RANKL-mediated osteoclast differentiation. J Cell Biochem 102:1300–1307PubMedCrossRef

94.

Mattey DL, Nixon N, Dawes PT, Kerr J (2005) Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis. Ann Rheum Dis 64:1190–1194PubMedCrossRef

95.

van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8:R151PubMedCrossRef

96.

Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173–1177PubMedCrossRef

97.

Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M (2008) Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 31:175–179PubMedCrossRef

98.

Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, De Matias JM, Martin J, Dessein PH, Llorca J (2008) Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 26:311–316PubMed

99.

Trocmé C, Marotte H, Baillet A, Pallot-Prades B, Garin J, Grange L, Miossec P, Tebib J, Berger F, Nissen MJ, Juvin R, Morel F, Gaudin P (2009) Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 68:1328–1333PubMedCrossRef

100.

Astbury C, Platt R, Dixon JS, Le Gallez P, Hill J, Bird HA (1993) Optimizing the assessment of disease activity during treatment with anti-rheumatoid drugs. Br J Rheumatol 32:467–473PubMedCrossRef

101.

Veale DJ, Maple C, Kirk G, McLaren M, Belch JJ (1998) Soluble cell adhesion molecules–P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheumatol 27:296–299PubMedCrossRef

102.

Espinola RG, Pierangeli SS, Gharavi AE, Harris EN (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 87:518–522PubMed

103.

Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, Elisaf MS, Kitas GD (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:72–75CrossRef

104.

Maitz P, Kandler B, Fischer MB, Watzek G, Gruber R (2006) Activated platelets retain their potential to induce osteoclast-like cell formation in murine bone marrow cultures. Platelets 17:477–483PubMedCrossRef

105.

Gasparyan AY, Stavropoulos-Kalinoglou A, Toms TE, Douglas KM, Kitas GD (2010) Association of mean platelet volume with hypertension in rheumatoid arthritis. Inflamm Allergy Drug Targets 9:45–50

Titel: Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications
verfasst von: Armen Yuri Gasparyan
Antonios Stavropoulos-Kalinoglou
Dimitri P. Mikhailidis
Karen M. J. Douglas
George D. Kitas
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 2/2011
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-010-1446-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Incidence and predictors of osteonecrosis among cyclosporin- or tacrolimus-treated renal allograft recipients

A case of adult-onset Still’s disease complicated with atypical pulmonary defect

Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome

Autoantibodies against oxidized low-density lipoprotein and lipid profile in patients with chronic periaortitis: case–control study

Facial palsy in a 2-month-old infant with Kawasaki disease

Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin